Stock analysts expect West Pharmaceutical Services, Inc. (NYSE:WST – Get a rating) will report earnings of $2.18 per share for the current quarter, Zacks Investment Research reports. Three analysts have made earnings estimates for West Pharmaceutical Services, with the lowest EPS estimate of $2.07 and the highest estimate of $2.26. West Pharmaceutical Services reported earnings per share of $2.05 in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.3%. The company is expected to announce its next earnings report on Thursday, May 5.
On average, analysts expect West Pharmaceutical Services to report annual earnings of $9.28 per share for the current fiscal year, with EPS estimates ranging from $9.21 to $9.36. For the next fiscal year, analysts expect the company to report earnings of $10.35 per share, with EPS estimates ranging from $9.85 to $10.81. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts who cover West Pharmaceutical Services.
West Pharmaceutical Services (NYSE: WST- Get a rating) last released its quarterly earnings data on Thursday, February 17. The medical device supplier reported earnings per share of $2.04 for the quarter, beating the consensus estimate of $1.92 by $0.12. West Pharmaceutical Services achieved a net margin of 23.37% and a return on equity of 31.20%. The company posted revenue of $730.80 million in the quarter, compared to $710.20 million expected by analysts. During the same quarter of the previous year, the company achieved EPS of $1.34. The company’s revenue increased 26.0% year over year.
Several equity analysts have commented on WST shares. William Blair repeated an “outperform” rating on West Pharmaceutical Services shares in a Tuesday, February 22 report. Zacks Investment Research downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a target price of $450.00 for the stock. in a report on Saturday, January 8. Ultimately, StockNews.com downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a report on Monday, February 21.
Several institutional investors have recently changed their positions in the stock. Thrivent Financial for Lutherans increased its holdings of West Pharmaceutical Services shares by 0.5% during the third quarter. Thrivent Financial for Lutherans now owns 4,765 shares of the medical device supplier worth $2,023,000 after buying 23 more shares in the last quarter. Kentucky Retirement Systems increased its holdings of West Pharmaceutical Services shares by 0.6% in the fourth quarter. Kentucky Retirement Systems now owns 4,385 shares of the medical device supplier valued at $2,057,000 after buying 25 additional shares in the last quarter. Global Retirement Partners LLC increased its holdings of West Pharmaceutical Services shares by 39.1% during the third quarter. Global Retirement Partners LLC now owns 96 shares of the medical device supplier valued at $41,000 after buying 27 additional shares in the last quarter. Eudaimonia Partners LLC increased its equity stake in West Pharmaceutical Services by 1.7% during the third quarter. Eudaimonia Partners LLC now owns 1,674 shares of the medical device supplier valued at $711,000 after buying 28 additional shares in the last quarter. Finally, Fulcrum Equity Management increased its stake in West Pharmaceutical Services by 1.0% during the 4th quarter. Fulcrum Equity Management now owns 2,797 shares of the medical device supplier worth $1,312,000 after acquiring 28 additional shares in the last quarter. 91.24% of the shares are currently held by institutional investors.
WST Stock opened at $372.88 on Tuesday. The company has a quick ratio of 2.30, a current ratio of 2.93 and a debt ratio of 0.09. West Pharmaceutical Services has a 12-month low of $259.14 and a 12-month high of $475.35. The company has a market capitalization of $27.70 billion, a P/E ratio of 42.86, a P/E/G ratio of 4.33 and a beta of 1.06. The company’s 50-day moving average price is $395.28 and its two-hundred-day moving average price is $421.39.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 4. Investors of record on Wednesday, April 20 will receive a dividend of $0.18 per share. This represents an annualized dividend of $0.72 and a dividend yield of 0.19%. The ex-dividend date is Tuesday, April 19. West Pharmaceutical Services’ dividend payout ratio (DPR) is currently 8.28%.
About West Pharmaceutical Services (Get a rating)
West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines, and consumer health products. It operates through the following business segments: Proprietary Products and Contract Manufactured Products. The Proprietary Products segment offers proprietary drug packaging, containment and delivery products, as well as analytical laboratory services, to biologic, generic and pharmaceutical drug customers.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in West Pharmaceutical Services right now?
Before you consider West Pharmaceutical Services, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and West Pharmaceutical Services was not on the list.
While West Pharmaceutical Services currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here